In the past week, three generic Zantac drugs have been recalled from pharmacy shelves across the U.S as concern grows that the popular heartburn and ulcer drug Zantac is linked to an increased risk of cancer.

On Tuesday, Amneal Pharmaceuticals recalled dozens of lots of Ranitidine Tablets and Ranitidine Syrup – Specifically, all lots of 150 mg and 300 mg tablets, and 15mg/ml syrup were pulled from the market.

The decision was made amid concerns that the Ranitidine Tablets and Ranitidine Syrup contain dangerous amounts of N-Nitrosodimethylamine (NDMA), a probable human carcinogen, above the limit established by the FDA.

So far, there have been nine Ranitidine recalls.

According to Amneal Pharmaceuticals, no adverse events have been reported as a result of this recall, to date.

Amneal’s Ranitidine follows two similar Ranitidine recalls, all occurring within a week.

Aurobindo Pharma USA issued a recall of both Ranitidine Capsules and Ranitidine Syrup the prior Wednesday.

American Health Packaging issued a recall for Ranitidine Syrups two days later, on Friday.

 

THANK YOU FOR YOUR MESSAGE

One of our associates will follow up with you shortly